Elvitegravir

**Elvitegravir: A Potent Antiretroviral for HIV Treatment**

Elvitegravir is an integrase strand transfer inhibitor (INSTI) used to treat HIV-1 infection. It blocks the integrase enzyme, preventing the virus from integrating its genetic material into host cells and multiplying.

**Key Features:**

* Approved by the FDA in 2012
* Highly effective in suppressing viral replication
* Well-tolerated with a low risk of side effects
* Available as a combination tablet with other antiretrovirals

**Indication:**

Elvitegravir is indicated for adults and adolescents over 12 years of age with HIV-1 infection, in combination with other antiretrovirals.

**Dosage:**

The recommended dosage of elvitegravir is 150 mg once daily.

**Benefits:**

* Potent antiviral activity
* Excellent tolerability
* Reduces viral load to undetectable levels
* Improves immune function
* Prevents disease progression

**Keywords:**

* Elvitegravir
* HIV treatment
* Integrase inhibitor
* Antiretroviral
* HIV-1